Weekend hikes gradually turn into strolls around the block. Joyful games of fetch or Frisbee are rare. Even standing up after a nap becomes a daunting task for your faithful friend.
Anyone who has had a lifelong canine companion has also had the difficult experience of watching that companion age, becoming increasingly stiff and less interested in play. The cause is usually osteoarthritis, which affects nearly one in every five dogs. The progressive, chronic degeneration of cartilage characteristic of this condition can occur in various joints and at almost any age, and the pain that results can be debilitating.
Geriatric pets most commonly develop it in the hip, stifle (knee) or elbow; however, it is also often seen in dogs with hip or elbow dysplasia as early as one to two years of age. Treatments range from supplements and antiinflammatory medications to surgical intervention and, increasingly, stem cell therapy.
Over the last decade, regenerative medicine, which has been around in the human sphere for nearly a quarter of a century, has become more common in veterinary medicine, and stem cell therapy is at the forefront. Stem cells are the body’s way of regenerating itself. Biological “blank slates,” they have the potential to specialize into one of many types of cells—skin, muscle, nerve, bone, tendon or ligament—and virtually any organ, and can be found in every organ in the body.
GET THE BARK IN YOUR INBOX!
Sign up for our newsletter and stay in the know.
According to Dr. Samuel Franklin, assistant professor of small animal orthopedic surgery at the University of Georgia, a good candidate for the therapy “has failed treatment with less invasive and less expensive treatment and has arthritis that does not benefit from surgery.” Franklin also notes that while stem cell therapy helps modulate inflammation, “stem cells do not regenerate cartilage.”
In 2005, Dr. Brian Voynick of the American Animal Hospital in Randolph, N.J., was the first U.S. veterinarian to use stem cell therapy in dogs. He recommends it for young dogs with early signs of hip dysplasia and lameness because it is less invasive and more proactive than surgery.
“In cases of hip dysplasia, we see [improvement in] greater than 90 percent of cases—better mobility, less or no lameness, and increased quality of life. Sometimes, we see improvement on radiographs,” says Voynick. These results are typical when the therapy is used in conjunction with platelet rich plasma (PRP), a concentrated mix of platelets and growth factors taken from the patient’s own blood. According to Voynick, PRP turbocharges the cells’ activation. Once injected, stem cells have an anti-inflammatory effect within the joint and contribute to the reformation and architectural organization of the tissues.
Voynick recalls a case of a dog with severe hip osteoarthritis treated with stem cell therapy and PRP. “[Before treatment] she could not stand up from a lying position. Three days later, she was walking and wagging her tail.”
Normally, however, the response is not quite so dramatic. Though improvement in lameness and pain is sometimes seen within the first week, it more commonly comes within a period of about 90 days. The exact duration of the injection’s effectiveness is not known, but it is thought that, at least initially, monthly injections are most beneficial. Patients are rechecked at 30, 60 and 90 days post-treatment, and injections may be repeated if lameness returns.
Stem cell therapy is also being used for osteoarthritis resulting from cranial cruciate ligament (CCL) injuries. This common injury of the canine knee is more often seen in large-breed dogs but can affect dogs of all sizes. CCL injuries may be treated medically with rest and medication, or they may require surgery.
“With a full [CCL] tear, we want the stabilization of surgery,” says Voynick, adding that stem cell therapy can be beneficial post-operatively during rehabilitation, especially if the injury is accompanied by muscle loss.
Franklin warns that more research is needed to support the results of stem cell therapy. “There is no evidence that [stem cell therapy] is any more beneficial than other treatments that are less invasive and less expensive.” Among these treatments are injections of hyaluronic acid, steroids or PRP. And, says Voynick, “Stem cell therapy should not be used in patients with infections or cancer. Stem cells target inflammation and can exacerbate disease in these cases.”
The process itself is relatively straightforward. Stem cells are either embryonic or somatic (adult), the latter of which can be retrieved from bone marrow or adipose tissue (fat). Due to the ease of collection, fat is usually the source of stem cells for use in companion animals. Fat-derived stem cells do not need to be cultured and can, therefore, be sent for processing and returned in as little as 48 hours.
Harvesting the fat is much less invasive than a spay. It is commonly taken from the shoulder, lumbar region or falciform ligament (a fatty ligament attaching the liver to the body wall). The 20-minute surgery is performed under general anesthesia and the fat is then sent to a laboratory, where it yields a product called stromal vascular fraction (SVF).
Once the SVF is in hand, the veterinarian will sedate the dog and inject SVF into the affected joint(s); it may also be injected into the bloodstream intravenously. Any remaining SVF is usually stored for future treatments. Although as with any surgery, there is risk when undergoing anesthesia to harvest the fat tissue, stem cell therapy is generally very safe. And, since SVF is derived from the dog’s own cells, the rate of immune reactions is extremely low.
Treatment with stem cell therapy isn’t easy on the wallet, however. Surgery, processing and the initial injection can range between $2,000 and $3,000, close to the cost of some surgical treatments. There are also no guarantees, and surgery may still be required if stem cell therapy fails. As Franklin, who recommends a case-by-case assessment on the value of stem cell therapy to an individual dog, notes, “It’s all about pros and cons—[deciding] what will be best for the patient.”